Ana Sayfa
Piyasalar
Grafikler ve Fikirler
Algo
Haberler
Store
Aracı Kurumlar
İndir
Ekonomik Takvim
Alım-Satım Sinyalleri
Web Terminali
Heatmap
Arama yapmak için
/
tuşuna basın: @kullanıcı, $sembol, ...
Ara
Giriş yap
Hesap oluştur
Türkçe
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Français
Italiano
LYEL
#2859
Lyell Immunopharma, Inc. Common Stock
23.840
0
USD
+2.01%
Sektör:
Sağlık Hizmetleri
Baz:
USD
Kar Para Birimi:
USD
Günlük Aralık
Yıllık Aralık
Günlük Değişim
+2.01%
Aylık Değişim
+11.56%
6 aylık değişim
-1.45%
Yıllık Değişim
-1.45%
Önceki Kapanış
23.370
0
Open
23.840
0
Bid
Ask
Low
23.840
0
High
23.840
0
Hacim
33
Piyasalar
ABD Borsası
Sağlık Hizmetleri
LYEL
Open full chart
Financials
Overview
Rapor
Statistics
Quarterly
Annual
Value
Q4, 24
Q1, 25
Q2, 25
Q3, 25
Q4, 25
TTM
Key stats
Total common shares outstanding
14.76 M
14.77 M
19.21 M
21.22 M
23.31 M
—
Valuation ratios
Enterprise value
83.35 M
38.56 M
71.02 M
221.01 M
657.21 M
987.81 M
Price to earnings ratio
-0.49
-0.43
-0.36
-0.71
-1.92
-3.42
Price to sales ratio
2 743.4
2 157.67
1 960.25
6 064.93
14.61 K
24.8 K
Price to cash flow ratio
-1.03
-0.83
-0.71
-1.45
-3.51
-6.49
Price to book ratio
0.44
0.08
0.08
0.18
2.12
2.46
Enterprise value to EBITDA ratio
-0.25
-0.11
-0.21
-0.67
-2.55
-3.54
Profitability ratios
Return on assets %
-0.39
-0.12
-0.11
-0.1
-0.41
-0.74
Return on equity %
-0.5
-0.16
-0.14
-0.12
-0.57
-0.98
Return on invested capital %
—
—
—
—
-450.21
—
Gross margin %
100
100
100
100
100
400
Operating margin %
-1.83 M
-819.53 K
-589.25 K
-248.35 K
-2.13 M
-3.78 M
EBITDA margin %
-1.78 M
-770.37 K
-550.06 K
-231.25 K
-2.09 M
-3.64 M
Net margin %
-1.74 M
-745.64 K
-533.55 K
-258.97 K
-2.35 M
-3.88 M
Liquidity ratios
Quick ratio
—
—
—
—
—
—
Current ratio
7.06
7.49
7.65
10.3
5.28
30.71
Inventory turnover
—
—
—
—
—
—
Asset turnover
0
0
0
0
0
0
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
Long term debt to total assets ratio
—
—
—
—
—
—
Long term debt to total equity ratio
—
—
—
—
—
—
Per share metrics
Operating cash flow per share
-3.61
-3.71
-2.33
-1.56
-1.89
-9.49
EBIT per share
-15.39
-3.89
-3.19
-2.04
-7.47
-16.58
EBITDA per share
-15
-3.65
-2.97
-1.9
-7.33
-15.86
Total debt per share
—
—
—
—
—
—
Cash per share
28.34
20.41
18.71
17.5
14.46
71.08
Net current asset value per share
29.03
20.95
19.08
17.97
15.27
73.26
Tangible book value per share
29.28
22.81
20.21
18.02
14.52
75.55
Working capital per share
24.92
18.16
16.58
16.22
12.38
63.34
Book value per share
29.28
22.81
20.21
18.02
14.52
75.55
Haberler
Lyell Immunopharma Stock (LYEL) Slides Despite Praise from a Top Wall Street Analyst - TipRanks.com
Morning News Wrap-Up 4/10/26: Today’s Biggest Stock Market Stories! - TipRanks.com
Lyell Immunopharma: Strong Early CAR-T Data, And Now A More Measured Bet (NASDAQ:LYEL)
H.C. Wainwright, Lyell Immunopharma hissesi için al önerisini korudu
Citizens, Lyell Immunopharma hissesi için tavsiyesini korudu
Citizens reiterates Lyell Immunopharma stock rating on trial progress
Avago, Lumentum among market cap stock movers on Monday
Lyell Immunopharma 50 milyon dolarlık hisse satışını tamamladı
Lyell Immunopharma closes $50M equity tranche, names new CFO
Citizens, Lyell Immunopharma hissesini üstün performans ile başlattı, hedef 34 dolar
Citizens initiates Lyell Immunopharma stock at outperform, $34 target
Lyell Immunopharma, Inc. (LYEL) Presents at TD Cowen 46th Annual Health Care Conference Transcript